In an exclusive with Proactive, Thomas Warner sat down with Redx Pharma PLC (AIM:REDX)'s chief financial officer, Peter Collum, to discuss the company's recent £14.1mln fundraiser and what it means for the future of the drug developer.
As the clinical-stage biotechnology company delves deeper into its groundbreaking research, Collum sheds light on their portfolio development plan, the potential of Redx's lead asset Zelasudil, and it collaboration with prominent pharmaceutical companies.
Thomas Warner: Let's start with the £14.1mln fundraising. Why was this move necessary, and how does it position Redx Pharma for the future?
Peter Collum: This fundraise showcases the unwavering support from our current investors. The additional capital ensures we can proceed with our ambitious ROC portfolio development plan, with an extended cash runway into Q3 of next year. The funds will be pivotal in achieving milestones, especially concerning our lead asset, Zelasudil.
TW: Let's delve deeper into Zelasudil. Why is it being touted as such a breakthrough, especially for conditions like IPF?
PC: IPF is a particularly challenging condition, with limited therapeutic options. Zelasudil, our selective ROCK2 inhibitor, presents a ray of hope. Our ongoing Phase 2a study, which will yield results in the first half of next year, is pivotal in this context. We also see potential for Zelasudil in treating other fibrosis-related conditions.
TW: Redx's focus on ROC inhibitors is evident. For the uninitiated, could you break down the significance of this approach?
PC: Absolutely. Rock inhibition holds immense promise due to its applicability across a spectrum of diseases, especially those with underlying fibrosis. However, the development journey is intricate. Redx's success in pioneering a range of rock inhibitors is a testament to our commitment and expertise. This differentiates us in the biotech landscape.
TW: Speaking of differentiation, Redx Pharma is also venturing into treatments for Fibrostenosis in Crohn's patients. Can you shed light on this?
PC: Of course. Crohn's is a debilitating condition, with a subset of patients developing fibrosis in the gut. Our oral pan-ROCK inhibitor, RXC008, is being developed precisely for these patients. The current treatment landscape is limited to invasive surgeries, so RXC008 could be a game-changer.
TW: Collaboration seems to be a cornerstone for Redx. Could you discuss the significance of your partnerships with other pharmaceutical giants?
PC: Collaborations amplify our reach and potential. Our partnerships, notably with Jazz Pharmaceuticals and AstraZeneca, have been mutually rewarding. These alliances not only validate our research but also open avenues for further exploration.
TW: Redx's achievements in drug development are commendable. What drives the company's success?
PC: Our foundational strength lies in developing high-calibre small-molecule compounds. We've successfully introduced five compounds into clinical stages, a testament to our team's prowess. Our recent accolades, like the approval of proto Brut nib, underscore our capabilities.
TW: As we wrap up, what's the overarching vision for Redx Pharma in the coming years?
PC: Our goal is unwavering: to pioneer treatments that make a tangible difference. With a robust pipeline, strategic collaborations, and a dedicated team, we're poised for transformative breakthroughs. As always, there's a lot on our horizon, and we're brimming with anticipation for the future.